IPSC vs. IVVD, KNTE, BLUE, NKTX, ALVR, CRGX, TECX, SRRK, PRME, and RGNX
Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Invivyd (IVVD), Kinnate Biopharma (KNTE), bluebird bio (BLUE), Nkarta (NKTX), AlloVir (ALVR), CARGO Therapeutics (CRGX), Tectonic Therapeutic (TECX), Scholar Rock (SRRK), Prime Medicine (PRME), and REGENXBIO (RGNX). These companies are all part of the "medical" sector.
Century Therapeutics (NASDAQ:IPSC) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, community ranking, institutional ownership, dividends, profitability and earnings.
Century Therapeutics has higher revenue and earnings than Invivyd. Century Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.
Century Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
Century Therapeutics currently has a consensus target price of $13.80, suggesting a potential upside of 452.00%. Invivyd has a consensus target price of $11.33, suggesting a potential upside of 758.59%. Given Invivyd's stronger consensus rating and higher possible upside, analysts clearly believe Invivyd is more favorable than Century Therapeutics.
In the previous week, Invivyd had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 3 mentions for Invivyd and 2 mentions for Century Therapeutics. Invivyd's average media sentiment score of 0.49 beat Century Therapeutics' score of 0.43 indicating that Invivyd is being referred to more favorably in the news media.
Invivyd has a net margin of 0.00% compared to Century Therapeutics' net margin of -9,742.41%. Century Therapeutics' return on equity of -59.74% beat Invivyd's return on equity.
Century Therapeutics received 22 more outperform votes than Invivyd when rated by MarketBeat users. However, 66.67% of users gave Invivyd an outperform vote while only 62.50% of users gave Century Therapeutics an outperform vote.
50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 6.8% of Century Therapeutics shares are held by company insiders. Comparatively, 17.9% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Invivyd beats Century Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Century Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Century Therapeutics Competitors List
Related Companies and Tools
